Hi @ montana,
Yes, you are correct about the consensus about these 2 medications. On the other hand, it is true that my observation could be considered as anecdotal evidence but I am not the only patient to observe this personally. There is empirical evidence on this. Gilead during their clinical trials observed this in about 6% of the participants.There are other studies that have looked into this and have concluded that yes they see these increases in LDL and triglycerides levels, but don’t understand why or what is leading to this. Lipid Changes After Switch From TDF to TAF in the OPERA Cohort: LDL Cholesterol and Triglycerides
, , , , , ,
Open Forum Infectious Diseases, Volume 9, Issue 1, January 2022, ofab621, https://doi.org/10.1093/ofid/ofab621
Published:08 December 2021
is a link to one of those:
I was sharing this experience so other patients will be aware that this could happen and they should not panic when it does. If you remember I also stressed on the importance of continued monitoring and saying that patients will react differently to any of these antivirals. Not every patient on Vemlidy will experience this, but some patients will. This seems to be a fact, that some people will and others will not. There is no clear understanding why this is so. I hope this helps clarify things. Glad we both can agree that it is a problem but there is no clear understanding of why or how it is happening. Best, Bansah1.
Note: This has also been discussed back in August last here. Check under here: